HOME >> MEDICINE >> NEWS
GL701 (prasterone) significantly reduces lupus flares

Philadelphia, Pa. - Oct. 31, 2000 - The incidence of debilitating flares or exacerbations that systemic lupus erythematosus (SLE or lupus) patients experience, some resulting in hospitalization, significantly declined with the use of GL701, according to a Phase III placebo-controlled, double-blind multicenter study conducted in Taiwan and presented at the 64th Annual Scientific Meeting of the American College of Rheumatology in Philadelphia. The drug used in this study is similar to Genelabs Technologies, Inc. (Nasdaq:GNLB) formulation of its investigational drug GL701. The study reported here today was conducted by Genelabs Biotechnology Co., Ltd. of Taiwan, a licensee of Genelabs Technologies, Inc.

"GL701 significantly reduced the percent of patients with flares. Since flares can punctuate the remission periods that lupus patients experience, the potential for this investigational drug to increase the duration of remission and decrease the number of flares that require hospitalization is an important therapeutic advance," says Deh-Ming Chang, M.D., coauthor of the study and Professor and Director of Rheumatology/Immunology at the Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

In the study, Chang and his colleagues compared GL701 to placebo among 119 Taiwanese women with lupus. Patients were evaluated in a randomized double-blind comparison of GL701, 200 mg or placebo daily for 24 weeks. Investigators evaluated efficacy based on change in Systemic Lupus Activity Measure (SLAM) and change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), which measure disease activity; physician and patient visual analog scales (VAS), which measure quality of life parameters; and percent of patients with definite flares.

Study results show that 18 percent of patients receiving GL701 experienced flares, compared to 34 percent of patients on placebo, a 46 percent reduction, which was significant (p=0.04). Moreover, no GL701 pa
'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000


Page: 1 2 3

Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: prasterone significantly reduces lupus flares

(Date:7/7/2015)... ... ... Law Group is pleased to announce the relocation of the firm's headquarters to 225 ... a state of the art building, located with easy access to New York City's ... "We are pleased to service our clients from such a premier location and we ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... SC&H Group, ... Service, which aims to give back to the community through company-wide volunteering efforts. , ... SC&H Group dedicate the day to assisting those in need throughout Baltimore and Washington ...
(Date:7/7/2015)... ... , ... At the end of June Pacific Prime Renewals team in Hong Kong announced ... by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the ... explained, “We send anything between 300 and 600 pieces of paper per month. Not to ...
(Date:7/7/2015)... ... 07, 2015 , ... Summer is a great time to get outside and ... sharing some safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the ... , Start slowly. Going from no activity to several hours of activity ...
(Date:7/7/2015)... ... ... Healthpointe is proud to announce the addition of Dr. Pedro S. Alupay to ... evaluating and treating patients with orthopedic complaints, such as lumbar back pain or cervical ... Biology from the University of the East, Manila, Dr. Alupay earned his Doctorate of ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
(Date:7/7/2015)... 30, 2015 Research ... of the "Deciphering Global Major Pharmaceutical Companies, ... their offering. It has been publicly ... involved in a series of challenges in the ... in significant overcapacities in small molecule product manufacturing; ...
(Date:7/7/2015)...   Decision Resources Group finds that ... management in the U.S. versus the EU5. In ... EU5 nephrologists from approximately 1,870 dialysis patient charts ... commonly used renal medications in dialysis patients; however, ... the two regions.      Other key findings ...
(Date:7/7/2015)... California and BANGALORE , ... , a global technology provider of innovative clinical trial ... Reports, (Industry Standard Research Reports) recent publication named " ... Provider Performance (2015) ". ISR Reports is one of ... pharmaceutical industry, and this report evaluated 22 EDC and ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
Cached News: